Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Disseminated Intravascular Coagulation (DIC) Treatment Market Snapshot 2023 to 2033

The global disseminated intravascular coagulation (DIC) treatment market is expected to garner a market value of US$ 500 million in 2023 and is expected to accumulate a market value of US$ 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for disseminated intravascular coagulation (DIC) treatment registered a CAGR of 4% in the historical period 2018 to 2022.

The Disseminated Intravascular Coagulation (DIC) Treatment market is a segment of the healthcare industry that deals with the effective management of Disseminated Intravascular Coagulation (DIC). The Disseminated Intravascular Coagulation (DIC) Treatment market offers a range of products and services for the management and treatment of DIC. The market for DIC treatments is largely driven by the increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications, as well as advancements in diagnostic and treatment technologies.

Report Attribute Details
Expected Market Value (2023) US$ 500 Million
Anticipated Forecast Value (2033) US$ 814.45 Million
Projected Growth Rate (2023 to 2033) 5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Disseminated Intravascular Coagulation (DIC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Disseminated Intravascular Coagulation (DIC) Treatment reflected a value of 4% during the historical period, 2018 to 2022.

The increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications that can lead to DIC is driving the demand for DIC treatments. Studies suggest that estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). Treatment for Disseminated Intravascular Coagulation (DIC) involves addressing the underlying condition that is causing the disorder, as well as treating the symptoms of DIC itself.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Disseminated Intravascular Coagulation (DIC) Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Disseminated Intravascular Coagulation (DIC) Treatments is fuelling the market growth. Thus, the market for Disseminated Intravascular Coagulation (DIC) Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Disseminated Intravascular Coagulation (DIC) Treatment Market?

Increased Prevalence of Disseminated Intravascular Coagulation (DIC) in Elderly Population to Push the Market Growth

The global market for disseminated intravascular coagulation (DIC) treatment is driven by the growing advancements in treatment technologies, the development of new diagnostic technologies, and the availability of more effective treatments. In addition, increased awareness of DIC, especially amongst the geriatric population which is at higher risk of developing underlying conditions that can lead to DIC, has led to a higher healthcare expenditure globally contributing to the growth of the market. Furthermore, the prevalence of Disseminated Intravascular Coagulation (DIC) is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings and cater to the growing demand for minimally invasive treatments for DIC, by developing new, less invasive treatments.

In 2021, a new tool created by researchers to tackle disseminated intravascular coagulation (DIC) was announced. Although the technology was yet to undergo clinical trials, studies in rat models and on blood from DIC patients have shown promise. Brown and her team created a method using nanogel spheres. These spheres are specifically designed to attach to fibrin, the primary protein present in blood clots. By doing so, the spheres travel through the bloodstream and once they encounter a blood clot, they adhere to the fibrin. The goal is to find a clinical solution to this dilemma and the new tool, using nanogel spheres, offers promising results. The spheres are designed to bind to the main protein in clots, fibrin, and are loaded with tissue-type plasminogen activator, a drug that dissolves clots.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Disseminated Intravascular Coagulation (DIC) Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Disseminated Intravascular Coagulation (DIC) Treatment options.

Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, are expected to hinder the market growth. Furthermore, various alternative treatments for underlying conditions, such as chemotherapy for cancer or antibiotics for sepsis, can limit demand for DIC treatments.

Region-Wise Insights

How is the Disseminated Intravascular Coagulation (DIC) Treatment Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling growth of Disseminated Intravascular Coagulation (DIC) Treatment in Asia Pacific

The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, with a CAGR of 2.5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Disseminated Intravascular Coagulation (DIC) Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to healthcare. Increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Disseminated Intravascular Coagulation (DIC) Treatment in North America?

Technological Advancements Shaping Landscape for Disseminated Intravascular Coagulation (DIC) Treatment in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.

The Centre for Disease Control and Prevention (CDC), in its December 2022 update reported that, in 2021, the incidence of coronary heart disease and heart attack among adults over 18 years old in the United States was 4.9% and 3% respectively. The high prevalence of heart diseases in developed nations will drive the growth of the market. Additionally, the increasing number of research partnerships and favorable regulatory policies also play a significant role in driving the growth of the market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Diagnosis, Which Segment is Likely to Account for a Prominent Share?

D-Dimer segment is expected to hold a major market share

The growing incidence of Venous Thromboembolism (VTE) and the increasing occurrence of pulmonary and cardiovascular diseases caused by blood clots are also contributing to the demand for D-dimer testing. The use of automated analyzers for D-dimer testing has increased in recent years and is expected to grow further in the future. Research has shown that these analyzers significantly reduce laboratory processing time and improve clinical decision making. Furthermore, ongoing R&D efforts to expand the use of analyzers also drives their usage.

Considering these figures, the D-Dimer diagnosis segment of Disseminated Intravascular Coagulation (DIC) is projected to push the market growth. Such a high prevalence of the disease is anticipated to bolster the demand for Disseminated Intravascular Coagulation (DIC) Treatment among the patient population over the coming years.

By End-users, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the DIC treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target disease.

Market Competition

Key players in the market include pharmaceutical companies such as Pfizer, Inc., Pfizer Inc., Roche Holding AG, Sanofi, Bayer AG and Johnson & Johnson, as well as healthcare providers and technology companies among other global players.

  • In June 2022, LumiraDx expanded its cardiovascular testing portfolio with CE marking of its NT-proBNP test and a new exclusion claim for its D-Dimer test. With its new Exclusion Claim, the LumiraDx D-Dimer test may be used at the point of care (POC) in conjunction with a clinical pre-test probability assessment model to allow clinicians to rule out venous thromboembolism (VTE) in symptomatic patients.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 500 million
Market Value in 2033 US$ 814.45 million
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Diagnosis
  • End-User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Middle East & Africa
  • Oceania
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A
  • Pfizer Inc.
  • GSK Plc.
  • Novartis AG
  • Bayer AG
  • Eli Lily and Company
  • Merck & Co. Inc.
  • Allergan Plc.
  • AbbVie Inc.
  • Merck KGaA
  • Hikma Pharmaceuticals PLC
Customization Available Upon Request

Key Segments Profiled in the Disseminated Intravascular Coagulation (DIC) Treatment Industry Survey

Diagnosis:

  • Partial Thromboplastin Time (PTT)
  • Prothrombin Time (PT)
  • Fibrinogen Blood Test
  • D-dimer

End User:

  • Specialty Clinics
  • Homecare
  • Hospital

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Middle East & Africa
  • Oceania

Frequently Asked Questions

Which are the Key Asian Countries in the DIC Treatment Market?

China, India, and Japan are key Asian countries in the market.

Which Industry is the Key Consumer of DIC Treatment Market?

Hospital sector is gaining significant traction in the market.

How Much can the Market grow by 2033 in China?

A CAGR of 7% is expected for the DIC treatment market by 2033.

What is Current Market Valuation of the Market?

The DIC therapy market is currently valued at US$ 500 million.

How Big will be the Disseminated Intravascular Coagulation (DIC) Treatment Market by 2033?

The DIC therapy market is anticipated to reach US$ 814.45 million by 2033.

Table of Content

1. Executive Summary | Disseminated Intravascular Coagulation (DIC) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Medicines

        5.3.2. Transfusions

        5.3.3. Surgery

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033

        6.3.1. Partial Thromboplastin Time (PTT)

        6.3.2. Prothrombin Time (PT)

        6.3.3. Fibrinogen Blood Test

        6.3.4. D-dimer

    6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End-Users , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Homecare

    7.4. Y-o-Y Growth Trend Analysis By End-Users , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-Users , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Diagnosis

        9.2.4. By End-Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Diagnosis

        9.3.4. By End-Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Diagnosis

        10.2.4. By End-Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Diagnosis

        10.3.4. By End-Users

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment

        11.2.3. By Diagnosis

        11.2.4. By End-Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Diagnosis

        11.3.4. By End-Users

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Treatment

        12.2.3. By Diagnosis

        12.2.4. By End-Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Diagnosis

        12.3.4. By End-Users

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Treatment

        13.2.3. By Diagnosis

        13.2.4. By End-Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Diagnosis

        13.3.4. By End-Users

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Treatment

        14.2.3. By Diagnosis

        14.2.4. By End-Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Diagnosis

        14.3.4. By End-Users

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Treatment

        15.2.3. By Diagnosis

        15.2.4. By End-Users

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment

        15.3.3. By Diagnosis

        15.3.4. By End-Users

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Treatment

            16.1.2.2. By Diagnosis

            16.1.2.3. By End-Users

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Treatment

            16.2.2.2. By Diagnosis

            16.2.2.3. By End-Users

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Treatment

            16.3.2.2. By Diagnosis

            16.3.2.3. By End-Users

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Treatment

            16.4.2.2. By Diagnosis

            16.4.2.3. By End-Users

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Treatment

            16.5.2.2. By Diagnosis

            16.5.2.3. By End-Users

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Treatment

            16.6.2.2. By Diagnosis

            16.6.2.3. By End-Users

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Treatment

            16.7.2.2. By Diagnosis

            16.7.2.3. By End-Users

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Treatment

            16.8.2.2. By Diagnosis

            16.8.2.3. By End-Users

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Treatment

            16.9.2.2. By Diagnosis

            16.9.2.3. By End-Users

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Treatment

            16.10.2.2. By Diagnosis

            16.10.2.3. By End-Users

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Treatment

            16.11.2.2. By Diagnosis

            16.11.2.3. By End-Users

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Treatment

            16.12.2.2. By Diagnosis

            16.12.2.3. By End-Users

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Treatment

            16.13.2.2. By Diagnosis

            16.13.2.3. By End-Users

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Treatment

            16.14.2.2. By Diagnosis

            16.14.2.3. By End-Users

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Treatment

            16.15.2.2. By Diagnosis

            16.15.2.3. By End-Users

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Treatment

            16.16.2.2. By Diagnosis

            16.16.2.3. By End-Users

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Treatment

            16.17.2.2. By Diagnosis

            16.17.2.3. By End-Users

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Treatment

            16.18.2.2. By Diagnosis

            16.18.2.3. By End-Users

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Treatment

            16.19.2.2. By Diagnosis

            16.19.2.3. By End-Users

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Treatment

            16.20.2.2. By Diagnosis

            16.20.2.3. By End-Users

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Treatment

            16.21.2.2. By Diagnosis

            16.21.2.3. By End-Users

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Treatment

        17.3.3. By Diagnosis

        17.3.4. By End-Users

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. F. Hoffmann-La Roche Ltd.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Mylan N.V.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Teva Pharmaceutical Industries Ltd.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Sanofi

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Pfizer Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. GlaxoSmithKline plc

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Novartis AG

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Bayer AG

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Eli Lilly and Company

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Merck & Co., Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Allergan

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. AbbVie Inc.

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. Merck KGaA

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. Hikma Pharmaceuticals PLC

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by End-Users , 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by End-Users , 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End-Users, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 18: Global Market Attractiveness by Diagnosis, 2023 to 2033

Figure 19: Global Market Attractiveness by End-Users , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 38: North America Market Attractiveness by Diagnosis, 2023 to 2033

Figure 39: North America Market Attractiveness by End-Users , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Diagnosis, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End-Users , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 77: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 78: Europe Market Attractiveness by Diagnosis, 2023 to 2033

Figure 79: Europe Market Attractiveness by End-Users , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 97: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Diagnosis, 2023 to 2033

Figure 99: South Asia Market Attractiveness by End-Users , 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 117: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Diagnosis, 2023 to 2033

Figure 119: East Asia Market Attractiveness by End-Users , 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 137: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Diagnosis, 2023 to 2033

Figure 139: Oceania Market Attractiveness by End-Users , 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by End-Users , 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by End-Users , 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by End-Users , 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-Users , 2023 to 2033

Figure 157: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 158: MEA Market Attractiveness by Diagnosis, 2023 to 2033

Figure 159: MEA Market Attractiveness by End-Users , 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Blood Coagulation Analyzers Market

Published : July 2023

Healthcare

Coagulation Analysers Market

Published : October 2022

Explore Healthcare Insights

View Reports

Disseminated Intravascular Coagulation (DIC) Treatment Market